Sophia Genetics closed an oversubscribed underwritten public offering, securing $57.5 million of gross proceeds before underwriting discounts and commissions. The company sold 12,104,900 ordinary shares at $4.75 per share after underwriters exercised an option to purchase an additional 1,578,900 shares. Sophia said it intends to use proceeds for working capital and general corporate purposes, including research and development. The company also plans to expand features, applications, and data modalities of its Sophia DDM platform, alongside sales and marketing spending. The filing also highlights other contemporaneous capital-raises across diagnostics and genomics-adjacent companies, including convertible note offerings from NeoGenomics and Adaptive Biotechnologies, indicating continued access to structured financing in parts of the sector.